Results 21 to 30 of about 56,983 (273)
BMJ Open, 2020 Introduction Transparent collaborations between patient organisations (POs) and clinical research sponsors (CRS) can identify and address the unmet needs of patients and caregivers.
Ilaria Galetti +18 more
doaj +1 more source
Veterinary nanomedicine: Pros and cons
Veterinary Medicine and Science, Volume 9, Issue 1, Page 494-506, January 2023., 2023 Abstract In recent years, nanotechnology has improved life with continuous growth in different fields. Nanoparticles can be employed in industry, imaging, engineering, and various biomedical filed because of their special physicochemical properties like rapid, effective, highly specific solutions, higher stability, biodegradability, biocompatibility ...
Fariba Jafary +2 more
wiley +1 more source
Advanced Autoantibody Testing in Systemic Sclerosis
Diagnostics, 2023 Systemic sclerosis is a systemic autoimmune rheumatic disease characterized by immune abnormalities, leading to vasculopathy and fibrosis. Autoantibody testing has become an increasingly important part of diagnosis and prognostication.
Kholoud Almaabdi +2 more
doaj +1 more source
CD47 prevents the elimination of diseased fibroblasts in scleroderma
bioRxiv, 2020 Scleroderma is a devastating fibrotic autoimmune disease. Current treatments are partly effective in preventing disease progression, but do not remove fibrotic tissue. Here, we evaluated whether scleroderma fibroblasts take advantage of the “don’t-eat-me-
Tristan Lerbs +9 more
semanticscholar +1 more source
Thoracic Cancer, Volume 14, Issue 2, Page 135-142, January 2023., 2023 A total of 445 myasthenia gravis (MG) patients in which thymectomy was performed were included in this cohort. Nineteen patients (4.3%) developed a new autoimmune disease (AD) after thymectomy. The most common types of new onset ADs after thymectomy were Hashimoto's thyroiditis and rheumatoid arthritis (RA), which were different from those before ...
Wenxin Tian +9 more
wiley +1 more source
Fibrosing arthropathy in juvenile scleroderma
Современная ревматология, 2021 The group of scleroderma diseases includes a number of clinical entities, the main symptom of which is skin tightening. Scleroderma is a prominent example of these diseases, characterized by excessive synthesis and deposition of collagen in organs and ...
D. A. Dibrov +2 more
doaj +1 more source
Mortality and morbidity in scleroderma renal crisis: A systematic literature review
Journal of Scleroderma and Related Disorders, 2020 Objectives: The objective of this study was to systematically review the mortality and morbidity associated with scleroderma renal crisis and to determine temporal trends.
Hyein Kim +3 more
semanticscholar +1 more source
Adipocyte-specific Repression of PPAR-gamma by NCoR Contributes to Scleroderma Skin Fibrosis
Arthritis Research & Therapy, 2018 Background A pivotal role for adipose tissue homeostasis in systemic sclerosis (SSc) skin fibrosis is increasingly recognized. The nuclear receptor PPAR-γ is the master regulator of adipogenesis.
Benjamin Korman +5 more
doaj +1 more source
Systemic sclerosis sine scleroderma.
Advances in Clinical and Experimental Medicine, 2017 Systemic sclerosis is a rare generalized disease with scleroderma, i.e. skin thickening as one of the most common symptoms. The disease has 2 main subsets, diffuse and limited forms.
E. Kucharz, M. Kopeć-Mędrek
semanticscholar +1 more source
Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma
Proceedings of the National Academy of Sciences of the United States of America, 2019 Significance The key epigenetic regulator EZH2 plays a central role in fibrosis and abnormal angiogenesis in scleroderma. EZH2-target genes mediating profibrotic and antiangiogenic effects in scleroderma patients have been identified and characterized ...
P. Tsou +7 more
semanticscholar +1 more source